INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry…
MaaT PharmaApril 21, 2022
MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in…
MaaT PharmaApril 7, 2022
Monthly information regarding the total number of voting rights and shares comprising the share capital…
MaaT PharmaApril 4, 2022
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients…
MaaT PharmaMarch 28, 2022
MaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux Lyon, France, March…
MaaT PharmaMarch 21, 2022
MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT…
MaaT PharmaMarch 17, 2022
MaaT Pharma Reports Cash and Revenues for Full-Year 2021 As of December 31, 2021, cash…
adminociFebruary 28, 2022
Ce communiqué ne peut être distribué directement ou indirectement aux Etats-Unis d’Amérique, au Canada, en…
MaaT PharmaFebruary 9, 2022
MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem…
MaaT PharmaFebruary 8, 2022
